SCHEMBL1521748

SCHEMBL1521748

CNc1ncc2c(n1)N(C(C)C)C(=O)N(c1ccc(F)c(NC(=O)Nc3cc(C(C)(C)C)on3)c1)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
BRAF P15056 4/20 0.42
MAPK14 Q16539 5/20 0.39
MAPT P10636 3/20 0.39
HTT P42858 3/20 0.39
ATM Q13315 1/20 0.39
RET P07949 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CSF1R P07333 1/20 0.38
MAPK13 O15264 1/20 0.38
FLT3 P36888 2/20 0.37
RAF1 P04049 2/20 0.37
MAPK3 P27361 1/20 0.37
KRAS P01116 1/20 0.36
KDR P35968 1/20 0.36
MAP2K2 P36507 1/20 0.36
MAP2K1 Q02750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521552 0.89 BRAF (0.46) BRAFMAPK14RETMAPK13RAF1
SCHEMBL1521500 0.88 RAB9A (0.42) RAB9ANPC1BRAFMAPK14MAPT
SCHEMBL1521898 0.83 FGFR4 (0.35) BRAFRAF1KRASKDR
SCHEMBL1521974 0.81 CDK8 (0.47) BRAFMAPK14RETFLT3RAF1
SCHEMBL1521795 0.80 BRAF (0.47) BRAFMAPK14RETMAPK13RAF1
SCHEMBL1521670 0.78 BRAF (0.51) BRAFMAPK14RETMAPK13RAF1
SCHEMBL1521517 0.78 ABL1 (0.44) RAB9ANPC1MAPK14RETKDR
SCHEMBL1521598 0.77 BRAF (0.42) BRAFMAPK14MAPK13RAF1KRAS
SCHEMBL1521434 0.77 FGFR4 (0.38) KDR
SCHEMBL1522047 0.77 BRAF (0.46) BRAFMAPK14RETMAPK13RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 RAB9A 1244/4885NPC1 4287/4885BRAF 1/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 RAB9A 1244/4885NPC1 4287/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.